Medivir to present at the Pareto Securities´ Healthcare conference
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Pareto Securities´ Healthcare conference on September 7, 2022. CEO Jens Lindberg will present the company and the clinical development of the focus project fostroxacitabine bralpamide (fostrox) in primary liver cancer. The presentation will be held at 15.45 CET at Sergel Hub, Sveavägen 10A in Stockholm. The presentation will be available after the meeting on Medivirs website; www.medivir.com. For additional information, please contactMagnus Christensen, CFO, Medivir AB